Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Medicine Matters oncology

Lenalidomide (CC-5013; Revlimid®) is a thalidomide analog and oral immunomodulatory drug that has antiangiogenic, antiproliferative, and proapoptotic properties in patients with CTCL [26]. In a phase II trial, lenalidomide showed encouraging activity with acceptable toxicity in refractory advanced CTCL with an ORR of 28% [27]. Currently, there are multiple clinical trials underway for advanced CTCL investigating lenalidomide in combination with other agents including durvalumab and brentuximab vedotin among others.